EFFECTS OF KRN23, AN ANTI-FGF23 ANTIBODY, IN PATIENTS WITH TUMOR-INDUCED OSTEOMALACIA OR EPIDERMAL NEVUS SYNDROME-ASSOCIATED OSTEOMALACIA: INTERIM RESULTS FROM A PHASE 2 STUDY

著录项

• 来源
  《Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA》 |2017年第1期|共2页
• 作者

  Carpenter T.; Miller P. D.; Weber T.; Peacock M.; Ruppe M.; Insogna K.; Luca D.; Skrinar A.; San Martin J.; de Beur S. Jan;

  展开▼
• 作者单位

  Yale Univ Sch Med New Haven CT USA;

  Colorado Ctr Bone Res Lakewood CO USA;

  Duke Univ Durham NC USA;

  Indiana Univ Sch Med Indianapolis IN 46202 USA;

  Houston Methodist Hosp Houston TX USA;

  Yale Univ Sch Med New Haven CT USA;

  Ultragenyx Pharmaceut Inc Novato CA USA;

  Ultragenyx Pharmaceut Inc Novato CA USA;

  Ultragenyx Pharmaceut Inc Novato CA USA;

  Johns Hopkins Univ Sch Med Baltimore MD USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 骨科学（运动系疾病、矫形外科学）;
• 关键词